Compounded GLP-1s in 2026: the operator’s map.
The rules around compounded GLP-1s changed fast over the last two years, and a lot of coverage flattened the story into headlines. The reality for operators is more useful: a lawful pathway continues — and running it well comes down to documentation, sourcing, and claims discipline.
Lithos Staff
Photograph via UnsplashThe shortage-era rules that allowed broad compounding of semaglutide and tirzepatide ended when the FDA declared the shortages resolved (tirzepatide in late 2024, semaglutide in early 2025). What continues is the patient-specific pathway: compounding tailored to an individual patient’s documented clinical needs. Programs operating there succeed on three disciplines — clinical documentation that supports each prescription, pharmacy partners with verifiable sourcing, and marketing that describes the care rather than the copy. Diversifying alongside branded channels is smart risk management, not a retreat.
How the landscape shifted
Compounding law includes a shortage provision: while a drug is on the FDA’s shortage list, pharmacies may compound versions of it broadly. Branded semaglutide and tirzepatide spent 2022–2024 in shortage, and compounded GLP-1s made medical weight care affordable for a large population the branded supply chain wasn’t reaching.
The FDA declared tirzepatide’s shortage resolved in late 2024 and semaglutide’s in early 2025, and the wind-down periods that followed closed the broad-compounding chapter. What that did not end is compounding itself: the patient-specific pathway — preparations tailored to an individual patient’s documented clinical needs — is how compounding has always worked outside shortages, and it is where GLP-1 compounding operates today.
The pathway that continues — and what it asks of you
| Discipline | The standard | The operator’s job |
|---|---|---|
| Clinical documentation | Each prescription reflects an individualized clinical determination | Intake and charting that capture the rationale at prescribing time |
| Pharmacy sourcing | FDA-registered API with certificates of analysis; licensure in every ship-to state | Partner diligence, revisited on a schedule — their sourcing is your foundation |
| Marketing claims | Describe the care and customization, not equivalence to branded products | Claims review as a standing function, not a launch task |
| Product flexibility | Rules in this category move | A catalog that can shift products without rebuilding flows |
Operating defensibly in 2026
- Let the chart carry the program. The difference between a strong program and an exposed one is rarely the therapy — it is whether the individualized rationale is sitting in the record when someone asks. Build intake so the documentation writes itself.
- Know your pharmacy like a co-founder. Where the API comes from, which states are covered, what their inspection history looks like. Redundancy across partners keeps a licensure hiccup from becoming a patient-supply problem.
- Keep marketing on the right side of the line. The scrutiny in this category concentrates on claims — “same as [brand] for less” framing invites it; describing individualized, clinician-directed care does not.
- Diversify as insurance, not ideology. Branded direct-cash channels and coverage navigation alongside compounded offerings mean every future regulatory move — in either direction — is a catalog decision you make calmly.
- Watch the landscape actively. Litigation and guidance in this space are still moving. Programs that track it (or run on infrastructure that does) adjust early and quietly.
Frequently asked questions
Is compounded semaglutide still legal in 2026?
The patient-specific pathway continues: compounding tailored to an individual patient’s documented clinical needs — a formulation, strength, or combination a commercial product does not serve. What ended with the shortages is broad compounding of standard doses. The operator’s job is making sure every prescription genuinely sits in the first category, with documentation to match.
What documentation supports a patient-specific prescription?
A clinician’s individualized assessment showing why this patient needs this customized formulation — captured in the chart at prescribing time, not reconstructed later. Programs whose intake and charting produce that record by default are in a fundamentally stronger position.
How should we vet a compounding pharmacy partner?
Verify state licensure everywhere you ship, FDA-registered API sources with certificates of analysis, and the pharmacy’s own compliance posture. Their sourcing diligence is your program’s foundation.
Should we add branded products alongside compounded offerings?
Many programs run both — compounded therapy where clinically indicated, branded products through direct cash channels or coverage where they fit. Product diversity means a rule change is a catalog adjustment rather than an existential event.
From first call to first patient, in weeks.
A 15-minute intro call, sandbox credentials the same day, go-live in 3–4 weeks — new launches and existing patient bases alike.